ELUTIA INC.

Elutia develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients by addressing unmet medical needs and reducing complications such as infection, migration, erosion, implant rejection, and fibrosis. The company's operations cover research and development through the commercial distribution of biologic matrix products used in plastic and reconstructive surgery. On October 1, 2025, Elutia divested its cardiac implantable electronic device ("CIED") products, EluPro™ and CanGaroo®, to Boston Scientific Corporation ("BSC") and Cardiac Pacemakers Inc ("CPI") for an aggregate purchase price of up to $88.0 million in cash. EluPro was the first antibiotic-eluting biologic matrix envelope for use with CIEDs. Following this sale, Elutia is focused on advancing its drug-eluting biomatrix ("DEB") platform. This platform utilizes biologic matrix and local drug delivery capabilities to address complications in reconstructive procedures and surgical repair, such as infection, inflammation, and fibrosis. The company's lead development programs include NXT-41, a next-generation biologic matrix, and NXT-41x, which incorporates local antibiotic drug delivery into the NXT-41 matrix. NXT-41 is an advanced biomatrix designed for consistent handling and incorporation, enabling scalable manufacturing.